Treatment duration as a surrogate endpoint to evaluate the efficacy of crizotinib in sequential therapy for patients with advanced ALK‐positive non‐small cell lung cancer: A retrospective, real‐world study
Sign Up to like & getrecommendations! Published in 2019 at "Cancer Medicine"
DOI: 10.1002/cam4.2420
Abstract: Crizotinib has demonstrated good efficacy in patients with anaplastic lymphoma kinase (ALK)‐positive non‐small cell lung cancer (NSCLC). Continuing crizotinib therapy beyond progressive disease (CBPD) can achieve ongoing survival benefit in real‐world clinical practice. In terms… read more here.
Keywords: therapy; alk positive; efficacy; non small ... See more keywords
Lorlatinib Is Active in ROS1-Positive Non-Small Cell Lung Cancer.
Sign Up to like & getrecommendations! Published in 2020 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-rw2019-169
Abstract: In a phase I/II trial, lorlatinib was safe and effective in ROS1-positive non-small cell lung cancer. read more here.
Keywords: small cell; positive non; cancer; ros1 positive ... See more keywords
Uncommon ALK fusion partners in advanced ALK-positive non-small-cell lung cancer.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.8561
Abstract: 8561Background: The variants affect the efficacy of crizotinib in echinoderm microtubule protein-like-4 (EML4)- anaplastic lymphoma kinase (ALK) fusion-positive non–small-cell lung cancers (NSCLCs)... read more here.
Keywords: alk fusion; cell lung; non small; positive non ... See more keywords
Cytokine profiling of exosomes derived from the plasma of HIV-infected alcohol drinkers and cigarette smokers
Sign Up to like & getrecommendations! Published in 2018 at "PLoS ONE"
DOI: 10.1371/journal.pone.0201144
Abstract: Cytokines and chemokines circulate in plasma and may be transferred to distant sites, via exosomes. HIV infection is associated with dysregulation of cytokines and chemokines, which subsequently contribute to the pathogenesis of HIV. Alcohol and… read more here.
Keywords: cytokines chemokines; hiv; alcohol drinkers; positive non ... See more keywords
Alectinib after failure to crizotinib in patients with ALK-positive non-small cell lung cancer: results from the Spanish early access program
Sign Up to like & getrecommendations! Published in 2022 at "Oncotarget"
DOI: 10.18632/oncotarget.28244
Abstract: This retrospective observational study analyzed the clinical characteristics, treatment patterns and outcomes of 120 patients with advanced ALK-positive non-small-cell lung cancer (ALK+ NSCLC) according to data collected between November 2019 and October 2020 in 38… read more here.
Keywords: non small; small cell; positive non; alk positive ... See more keywords
Efficacy of Ceritinib After Alectinib for ALK-positive Non-small Cell Lung Cancer
Sign Up to like & getrecommendations! Published in 2018 at "In Vivo"
DOI: 10.21873/invivo.11418
Abstract: Background: Alectinib is a new standard treatment for treatment-naïve anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC); however, resistance ultimately develops in almost all patients, and data regarding the efficiency of ceritinib for such… read more here.
Keywords: alk positive; ceritinib; non small; positive non ... See more keywords
Matching-adjusted indirect comparison: entrectinib versus crizotinib in ROS1 fusion-positive non-small cell lung cancer.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of comparative effectiveness research"
DOI: 10.2217/cer-2020-0063
Abstract: Aim: To perform indirect treatment comparisons of entrectinib versus alternative ROS1 fusion-positive non-small cell lung cancer treatments. Methods: Relevant studies with crizotinib and chemotherapy as comparators of interest identified by systematic literature review were selected… read more here.
Keywords: versus crizotinib; ros1 fusion; positive non; non small ... See more keywords
Alectinib for treatment of ALK-positive non-small-cell lung cancer.
Sign Up to like & getrecommendations! Published in 2017 at "Future oncology"
DOI: 10.2217/fon-2016-0386
Abstract: Alectinib is a highly selective second-generation ALK inhibitor that is active against most crizotinib ALK resistance mutations, with a good penetration in CNS and a good safety profile. Thanks to the positive results of Phase… read more here.
Keywords: alk; alk positive; cell lung; non small ... See more keywords
Effectiveness of crizotinib versus entrectinib in ROS1-positive non-small-cell lung cancer using clinical and real-world data.
Sign Up to like & getrecommendations! Published in 2022 at "Future oncology"
DOI: 10.2217/fon-2021-1102
Abstract: Aims: To compare clinical trial results for crizotinib and entrectinib in ROS1-positive non-small-cell lung cancer and compare clinical trial data and real-world outcomes for crizotinib. Patients & methods: We analyzed four phase I-II studies using… read more here.
Keywords: world; small cell; non small; real world ... See more keywords
Indirect comparisons of brigatinib and alectinib for front-line ALK-positive non-small-cell lung cancer.
Sign Up to like & getrecommendations! Published in 2022 at "Future oncology"
DOI: 10.2217/fon-2022-0194
Abstract: Aim: To conduct an indirect treatment comparison (ITC) of the relative efficacy of brigatinib and alectinib for progression-free survival in people with tyrosine kinase inhibitor (TKI)-naive ALK-positive non-small-cell lung cancer (NSCLC). Methods: Final aggregate and patient-level… read more here.
Keywords: non small; brigatinib alectinib; small cell; positive non ... See more keywords
Efficacy of immune checkpoint inhibitor therapy in patients with RET fusion-positive non-small-cell lung cancer.
Sign Up to like & getrecommendations! Published in 2021 at "Immunotherapy"
DOI: 10.2217/imt-2021-0035
Abstract: Aim: To describe outcomes of patients with RET fusion-positive non-small-cell lung cancer (NSCLC) who received immune checkpoint inhibitor (ICI)-based treatments in the US. Patients & methods: Using de-identified Flatiron Health-Foundation Medicine NSCLC Clinico-Genomic and Guardant Health databases,… read more here.
Keywords: patients ret; positive non; ret fusion; non small ... See more keywords